Cybin announces grant of first u.s. composition of matter patent in support of its cyb005 phenethylamines program

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the united states patent and trademark office (“uspto”) has granted u.s. patent 12,122,741 (‘741) with claims to the composition of matter of lead preclinical candidates in the company's cyb005 phene.
CYBN Ratings Summary
CYBN Quant Ranking